 <h1>Zykadia Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ceritinib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ceritinib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Zykadia.</p><h2>In Summary</h2><p><b>Common side effects of Zykadia include:</b> abdominal pain, diarrhea, hyperglycemia, increased serum alanine aminotransferase, nausea, and vomiting. <b>Other side effects include:</b> interstitial pulmonary disease, pneumonitis, and prolonged qt interval on ecg.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ceritinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ceritinib (the active ingredient contained in Zykadia) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ceritinib:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>clay-colored stools</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>dry mouth</li>
<li>fever</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>headache</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>itching, skin rash</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>stomach pain or tenderness</li>
<li>sweating</li>
<li>swelling of the feet or lower legs</li>
<li>troubled breathing</li>
<li>unexplained weight loss</li>
<li>unsteadiness or awkwardness</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weakness in the arms, hands, legs, or feet</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest pain</li>
<li>chills</li>
<li>cough</li>
<li>fainting</li>
<li>general feeling of discomfort or illness</li>
<li>irregular heartbeat, recurrent</li>
<li>thickening of bronchial secretions</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ceritinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision or other changes in vision</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement</li>
<li>heartburn</li>
<li>pain or discomfort in the chest, upper stomach, or throat</li>
<li>seeing flashes or sparks of light</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ceritinib: oral capsule, oral tablet</i></p><h3>General</h3><p>The most common side effect resulting in dose reductions or interruptions were increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).  </p>
<p></p>
<p>The most common side effects leading to discontinuation were pneumonia, interstitial lung disease/pneumonitis, and decreased appetite.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (86%), nausea (80%), vomiting (60%), abdominal pain (54%), constipation (29%), esophageal disorder (16%)</p>
<p><b>Rare</b> (less than 0.1%): GI hemorrhage<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Very Common (10% or more): Hemoglobin decreased (84%), phosphate decreased (36%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Very Common (10% or more): ALT increased (80%), AST increased (75%), bilirubin increased (15%)<sup>[Ref]</sup></p><h3>Renal</h3><p>Very Common (10% or more): Creatinine increased (58%), phosphate decreased (36%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (34%), glucose increased (49%), lipase increased (28%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (16%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Interstitial lung disease/pneumonitis</p>
<p><b>Rare</b> (0.01% than 0.1%): Respiratory failure, pneumothorax, pulmonary tuberculosis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Neuropathy (17%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Vision disorder<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Prolonged QT, bradycardia</p>
<p><b>Rare</b> (less than 0.1%): Cardiac tamponade<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (52%)</p>
<p><b>Uncommon</b> (0.1% to 1%): General physical health deterioration<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (less than 0.1%): Sepsis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals, East Hanover, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Zykadia (ceritinib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: multikinase inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zykadia &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ceritinib: oral capsule, oral tablet</i></p><h3>General</h3><p>The most common side effect resulting in dose reductions or interruptions were increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).  </p><p></p><p>The most common side effects leading to discontinuation were pneumonia, interstitial lung disease/pneumonitis, and decreased appetite.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (86%), nausea (80%), vomiting (60%), abdominal pain (54%), constipation (29%), esophageal disorder (16%)</p><p><b>Rare</b> (less than 0.1%): GI hemorrhage<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Very Common (10% or more): Hemoglobin decreased (84%), phosphate decreased (36%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Very Common (10% or more): ALT increased (80%), AST increased (75%), bilirubin increased (15%)<sup>[Ref]</sup></p><h3>Renal</h3><p>Very Common (10% or more): Creatinine increased (58%), phosphate decreased (36%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (34%), glucose increased (49%), lipase increased (28%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (16%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Interstitial lung disease/pneumonitis</p><p><b>Rare</b> (0.01% than 0.1%): Respiratory failure, pneumothorax, pulmonary tuberculosis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Neuropathy (17%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Vision disorder<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Prolonged QT, bradycardia</p><p><b>Rare</b> (less than 0.1%): Cardiac tamponade<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (52%)</p><p><b>Uncommon</b> (0.1% to 1%): General physical health deterioration<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (less than 0.1%): Sepsis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals, East Hanover, NJ. </p><h2>More about Zykadia (ceritinib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: multikinase inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zykadia &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>